Khattar Jack A. 4
4 · SUPERNUS PHARMACEUTICALS, INC. · Filed Mar 16, 2026
Research Summary
AI-generated summary of this filing
Supernus (SUPN) CEO Jack A. Khattar Sells 35,000 Shares
What Happened Jack A. Khattar, President, CEO and a director of Supernus Pharmaceuticals (SUPN), sold a total of 35,000 shares in open-market transactions on March 13, 2026 for aggregate proceeds of about $1,763,124. The sales were reported as: 24,138 shares at a weighted average price of $50.09 (≈ $1,209,072), 10,742 shares at a weighted average price of $51.00 (≈ $547,842), and 120 shares at $51.75 (≈ $6,210). On the same date he also acquired 12,500 shares that were transferred to him from the KBT Trust without consideration (a re-registration/transfer).
Key Details
- Transaction date: March 13, 2026; Form 4 filed March 16, 2026.
- Sales: total 35,000 shares; total proceeds ≈ $1,763,124.
- 24,138 shares — weighted avg $50.09 (sales ranged $49.63–$50.62).
- 10,742 shares — weighted avg $51.00 (sales ranged $50.63–$51.54).
- 120 shares — $51.75.
- Acquisition: 12,500 shares transferred from the KBT Trust to Khattar without consideration (now owned directly).
- Some sales were made pursuant to a 10b5‑1 trading plan adopted December 12, 2025.
- Shares owned after the transactions are not specified in the filing.
Context Open‑market sales, especially those executed under a pre‑arranged 10b5‑1 plan, are commonly routine ways for insiders to diversify or raise cash and do not by themselves signal a change in view on the company. The 12,500‑share transfer from the trust is a non‑purchase transfer (not a market buy) and likewise does not necessarily indicate investment sentiment. The filing shows dates and weighted average prices and includes footnotes offering per‑trade price ranges if more detail is requested.
Insider Transaction Report
- Other
Common Stock
[F1]2026-03-13+12,500→ 1,241,144 total - Other
Common Stock
[F1]2026-03-13−12,500→ 993,100 total(indirect: By Trust) - Sale
Common Stock
[F2][F3]2026-03-13$50.09/sh−24,138$1,209,072→ 968,962 total(indirect: By Trust) - Sale
Common Stock
[F2][F4]2026-03-13$51.00/sh−10,742$547,842→ 958,220 total(indirect: By Trust) - Sale
Common Stock
[F2]2026-03-13$51.75/sh−120$6,210→ 958,100 total(indirect: By Trust)
Footnotes (4)
- [F1]The Reporting Person is filing this Form 4 to reflect the fact that 12,500 shares were transferred from the KBT Trust to the Reporting Person on March 13, 2026 without consideration and are now owned directly.
- [F2]Transaction made pursuant to a 10b5-1 trading plan adopted December 12, 2025.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.63 to $50.62. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.63 to $51.54. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.